TP53 and cancer: ALRN-6924 exhibits dual MDM2/MDMX inhibitory activities and has shown promise in preclinical studies and early-stage clinical trials to halt progression of cancers bearing WT p53 (Carvajal et al., 2018; Pairawan et al., 2021; Saleh et al., 2021).